Effect of molecular hydrogen treatment on Sepsis‐Associated encephalopathy in mice based on gut microbiota
Han Q, Bai Y, Zhou C, Dong B, Li Y, Luo N, Chen H, Yu Y. · CNS neuroscience & therapeutics. 2023;29(2):633-645.
What kind of evidence is this?
Preclinical
Controlled preclinical study
Metabolic and lipid health
Inhaled H₂
Not reported in this record.
Not reported in this record.
Methods at a glance
mice, tissue used to study metabolic and lipid health.
Preclinical study; group or assay counts reported in the full text include n=6.
100 ml/min
Full text reports inhaled H₂-containing gas. Detected intervention quantities or schedules: 2%, 100 ml/min, 10 min, 1000 ppb, 4 L/min.
Inhaled molecular H₂ at 2%; not classified as Brown’s gas without an H₂/O₂ composition.
H₂-related quantities reported in the intervention passages: 2%, 100 ml/min, 10 min, 1000 ppb, 4 L/min. Values are not combined across different experimental arms.
2 mL/min H₂, calculated from 2% H₂ and 100 mL/min total flow reported in the full text.
O₂ concentration and absolute O₂ flow were not both reported in the full article; no value is inferred.
Control or comparison condition reported in the full article; see the linked methods for arm-specific details.
Outcomes and reported result
survival or mortality, clinical symptoms or functional scores, tumor growth or cancer markers, inflammation and cytokines, oxidative-stress and antioxidant markers, apoptosis or cell injury
Article-reported result excerpt (24 words maximum): “The results showed that the expression levels of TNF‐α, IL‐6, and HMGB1 in the SAE group and SAE with molecular hydrogen treatment groups (SAE…” This excerpt is not a complete result summary; consult the linked full text for all positive and null findings.
The complete machine-readable article was checked for source identity, methods, intervention quantities, results, tables, funding and conflict declarations. This public record is based on the full article.
A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.
Cautions and applicability
Preclinical evidence only; findings do not establish a treatment effect in people. No funding statement was identified in the machine-readable full article; absence is not inferred. No explicit conflict statement was identified in the machine-readable full article; absence is not inferred.
Applies to the reported animal, cell or tissue model, not directly to patients.
Not reported in this record.
Not reported in this record.
Not reported in this record.
No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.
Sources and record status
PMID: 36468415 · DOI: 10.1111/cns.14043
A free full article is available through PubMed Central.
Official Europe PMC JATS full article and PubMed/PMC identifiers; structured full-text extraction and validation completed 8 August 2026.
2026-08-10